Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.62 |
| ▸ | HTR2C | P28335 | 5/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 11/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29548539 | 1.00 | HTR2A (0.62) | HTR2AHTR2CSIGMAR1NOTUMHTR1A | |
| SCHEMBL18911620 | 0.98 | HTR2A (0.60) | HTR2AHTR2CSIGMAR1NOTUMHTR1A | |
| SCHEMBL7300514 | 0.98 | HTR2A (0.60) | HTR2AHTR2CSIGMAR1NOTUMHTR1A | |
| SCHEMBL761931 | 0.94 | HTR2A (0.64) | HTR2AHTR2CSIGMAR1NOTUMHTR1A | |
| SCHEMBL30703022 | 0.94 | HTR2A (0.64) | HTR2AHTR2CSIGMAR1NOTUMHTR1A | |
| Acetic Acid SCHEMBL13279290 | 0.89 | HTR2A (0.55) | HTR2AHTR2CSIGMAR1 | |
| SCHEMBL18911621 | 0.86 | HTR2A (0.73) | HTR2AHTR2CSIGMAR1NOTUMHTR1A | |
| SCHEMBL24916793 | 0.77 | SIGMAR1 (0.50) | HTR2AHTR2CSIGMAR1 | |
| SCHEMBL6714308 | 0.77 | HTR2A (1.00) | HTR2AHTR2CSIGMAR1HTR1A | |
| SCHEMBL29391845 | 0.77 | HTR2A (1.00) | HTR2AHTR2CSIGMAR1NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1181282-A2 | BENZOTHIAZINONE AND BENZOXAZINONE COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 2002-02-27 | — | — | EP | claimed |
| WO-2000075139-A2 | BENZOTHIAZINONE AND BENZOXAZINONE COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 2000-12-14 | — | — | WO | claimed |
| US-20230120881-A1 | BINUCLEAR GOLD(I) COMPOUNDS FOR PHOTOCATALYSIS APPLICATIONS | University of Hong Kong Versitech Limited (CN) | 2023-04-20 | — | — | US | disclosed |
| US-20230120881-A1 | BINUCLEAR GOLD(I) COMPOUNDS FOR PHOTOCATALYSIS APPLICATIONS | University of Hong Kong Versitech Limited (CN) | 2023-04-20 | — | — | US | disclosed |
| EP-4122940-A1 | BINUCLEAR GOLD(I) COMPOUNDS FOR PHOTOCATALYSIS APPLICATIONS | Versitech Limited (CN) | 2023-01-25 | — | — | EP | disclosed |
| EP-4122940-A1 | BINUCLEAR GOLD(I) COMPOUNDS FOR PHOTOCATALYSIS APPLICATIONS | Versitech Limited (CN) | 2023-01-25 | — | — | EP | disclosed |
| EP-3290419-B1 | FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO LTD (CN) | 2019-08-07 | — | — | EP | disclosed |
| EP-3290419-B1 | FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO LTD (CN) | 2019-08-07 | — | — | EP | disclosed |
| EP-3312179-B1 | FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR | NANJING SANHOME PHARMACEUTICAL CO LTD (CN) | 2019-07-10 | — | — | EP | disclosed |
| EP-3312179-B1 | FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR | NANJING SANHOME PHARMACEUTICAL CO LTD (CN) | 2019-07-10 | — | — | EP | disclosed |
| EP-3489235-A1 | TRICYCLIC COMPOUND AS CRTH2 INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2019-05-29 | — | — | EP | disclosed |
| EP-1181282-A2 | BENZOTHIAZINONE AND BENZOXAZINONE COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 2002-02-27 | — | — | EP | disclosed |
| WO-2000075139-A2 | BENZOTHIAZINONE AND BENZOXAZINONE COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 2000-12-14 | — | — | WO | disclosed |
| US-5721245-A | ANTIINFLAMMATORY AGENTS, RESPIRATORY SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1998-02-24 | — | — | US | disclosed |
| EP-0384349-B1 | Substituted pyrroles | HOFFMANN LA ROCHE (CH) | 1994-04-27 | — | — | EP | disclosed |
| US-5192770-A | Antiemetic, anxiolytic, cognition activator | SYNTEX (U.S.A.) INC. (US) | 1993-03-09 | — | — | US | disclosed |
| US-5189041-A | Gastrointestinal and nervous system disorders, cardiovascular disorders, analgesics | SYNTEX (U.S.A.) INC. (US) | 1993-02-23 | — | — | US | disclosed |
| EP-0490263-A1 | Alpha-oxoacetamide derivatives | SYNTEX (U.S.A.) INC. (US) | 1992-06-17 | — | — | EP | disclosed |
| EP-0485962-A2 | New tricyclic compounds | SYNTEX (U.S.A.) INC. (US) | 1992-05-20 | — | — | EP | disclosed |
| EP-0384349-A1 | Substituted pyrroles | F. HOFFMANN-LA ROCHE AG (CH) | 1990-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230120881-A1 | BINUCLEAR GOLD(I) COMPOUNDS FOR PHOTOCATALYSIS APPLICATIONS | PPOX, AP3M1, AP2M1 | HTR2A 786/4885HTR2C 279/4885SIGMAR1 3534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.